Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1990): Rogerson SJ+, BMJ 301, 345
(1989): Goolsby PL, NEnglJMed321, 1198
Gianotti–Crosti syndrome
(2007): Karakas M+, JDermatol34(2), 117
(2001): Tay YK, Pediatr Dermatol 18(3), 262
Granuloma annulare
(2004): Criado PR+, J Eur Acad Dermatol Venereol 18(5), 603
(1998): Wolf F+, Eur J Dermatol 8(6), 435 (generalized)
Herpes zoster
Lichen nitidus
(2004): Fetil E+, Int J Dermatol 43(12), 956
Lichen planus
(2004): Calista D+, Int J Dermatol 43(8), 562
(2004): Criado PR+, J Eur Acad Dermatol Venereol 18(5), 603
(2002): Calista D+, World Congress Dermatol Poster, 0090
(2002): Schuh T+, Hautarzt 53(10), 650
(2001): Al-Khenaizan S, JAmAcadDermatol45(4), 614
(2001): Aron-Moar A+, Lupus 10(3), 237
(2000): Agrawal S+, JDermatol27(9), 618
(1999): Rebora A+, Dermatology 198(1), 1
(1999): Schupp P+, Int J Dermatol 38(10), 799
(1998): Ferrando MN+, Br J Dermatol 139(2), 350
(1998): Merigou D+, Ann Dermatol Venereol 125(6-7), 399
(1997): Gisserot O+, Presse Med 26(16), 760
(1995): Lefort A+, Ann Dermatol Venereol 122(10), 701
(1994): Aubin F+, Arch Dermatol 130(10), 1329
(1993): Trevisan G+, Acta Derm Venereol 73(1), 73
(1990): Ciaccio M+, Br J Dermatol 122, 424
Lichenoid eruption
(2004): Fetil E+, Int J Dermatol 43(12), 956
(2001): Usman A+, Pediatr Dermatol 18(2), 123
(1997): Saywell CA+, Australas J Dermatol 38(3), 152
Lupus erythematosus
(2005): Geier DA+, Autoimmunity 38(4), 295
(2000): Maillefert JF+, Arthritis Rheum 43(2), 468
(1999): Senecal JL+, Arthritis Rheum 42(6), 1307
(1998): Grotto I+, Vaccine 16(4), 329
(1996): Grezard P+, Ann Dermatol Venereol 123(10), 657
(1996): Guiserix J, Nephron 74(2), 441
(1994): Mamoux V+, Arch Pediatr 1(3), 307
(1992): Tudela P+, Nephron 62(2), 236
Morphea
(2000): Schmutz JL+, Presse Med 29(19), 1046
Petechiae
Purpura
(2004): Nuevo H+, Pediatr Infect Dis J 23(2), 183
(2002): Chave TA+, World Congress Dermatol Poster, 0093
(2001): Conesa V+, Haematologica 86(3), E09
(1999): Lliminana C+, Med Clin (Barc) 113(1), 39
(1999): Muller A+, Eur J Pediatr 158 Suppl 3, S209
(1998): Ronchi F+, Arch Dis Child 78(3), 273 (3 cases)
(1994): Poullin P+, Lancet 344(8932), 1293
Rash (sic)
Raynaud’s phenomenon
(1990): Cockwell P+, BMJ 301, 1281
Sclerotic plaques
(1998): Gout O+, Rev Neurol (Paris) 154(3), 205
Stevens–Johnson syndrome
Urticaria
(2000): Barbaud A+, Ann Dermatol Venereol 127(6-7), 662
(1998): Barbaud A+, Br J Dermatol 139(5), 925
(1998): Grotto I+, Vaccine 16(4), 329
Vasculitis
(2005): Geier DA+, Autoimmunity 38(4), 295
(2001): Saadoun D+, Rev Med Interne 22(2), 172
(1999): Le Hello C, Pathol Biol (Paris) 47(3), 252
(1999): Le Hello+, J Rheumatol 26(1), 191 (3 cases)
(1998): Bui-Quang D+, Presse Med 27(26), 1321
(1998): Grotto I+, Vaccine 16(4), 329
HEPATITIS B VACCINE 269
(1998): Masse I+, Presse Med 27(20), 965
(1997): Kerleau JM+, Rev Interne Med 18(6), 491 (necrotizing)
(1993): Allen MB+, Thorax 48(5), 580
(1990): Cockwell P+, BMJ 301, 1281
Mucosal
Aphthous stomatitis
(1996): Grezard P+, Ann Dermatol Venereol 123(10), 657
Oral lichenoid eruption
(2000): Pemberton MN+, Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 89(6), 717
Hair
Hair – alopecia
(2005): Geier DA+, Autoimmunity 38(4), 295
(1997): Wise RP+, JAMA 278(14), 1176 (46 cases)
Nails
Nails – lichen planus
(2005): Miteva L, Int J Dermatol 44(2), 142
Eyes
Optic neuropathy
(2005): Geier DA+, Autoimmunity 38(4), 295
(2004): Geier MR+, Clin Exp Rheumatol 22(6), 749
White dot syndrome
(1996): Baglivo E+, Am J Ophthalmol 122(3), 431
Other
Anaphylactoid reactions/Anaphylaxis
(2004): Prescrire Int 13(74), 218 (rare)
(2000): Prescrire Int 9(46), 59
(1998): Grotto I+, Vaccine 16(4), 329
(1996): MMWR Morb Mortal Wkly Rep 45(RR-12), 1
(1994): Stratton KR+, JAMA 271(20), 1602
Chills
Death
(1999): Niu MT+, Pediatr Adolesc Med 153(12), 1279
Erythromelalgia
(1999): Rabaud C+, J Rheumatol 26(1), 233
Hypersensitivity
Injection-site ecchymoses
Injection-site edema
(2005): Chowdhury A+, World J Gastroenterol 11(7), 1037
Injection-site erythema
(2005): Chowdhury A+, World J Gastroenterol 11(7), 1037
Injection-site induration
Injection-site nodules
Injection-site pain (22%)
(2005): Chowdhury A+, World J Gastroenterol 11(7), 1037
Injection-site pruritus
Injection-site reactions
(2005): Saenger R+, Vaccine 23(9), 1135 (2.3%)
Myalgia/Myositis/Myopathy/Myotoxicity
(2004): Geier MR+, Clin Exp Rheumatol 22(6), 749
Nephrotoxicity
(2007): Santoro D+, Clin Nephrol 67(1), 61
Pain
(2003): Jastaniah WA+, JPediatr143(6), 802
Polyarteritis nodosa
(2004): Begier EM+, J Rheumatol 31(11), 2181 (9 cases)
(2003): Bourgeais AM+, Ann Dermatol Venereol 130(2), 205
(2001): Saadoun D+, Rev Med Interne 22(2), 172
(1988): Le Goff P+, Presse Med 17, 1763
Pseudolymphoma
(2005): Maubec E+, JAmAcadDermatol52(4), 623
Serum sickness
(2002): Arkachaisri T, J Med Assoc Thai 85, S607